CK-19、CD-56在甲状腺乳头状癌和癌旁组织中的表达的研究进展  

Research Progress on the Expression of CK-19 and CD-56 in Papillary Thyroid Carcinoma and Para-Carcinoma Tissues

作　　者：文昊 耿中利 

机构地区：[1]新疆医科大学第四临床医学院,新疆 乌鲁木齐 [2]新疆维吾尔自治区中医医院普外二科,新疆 乌鲁木齐

出　　处：《临床医学进展》2023年第12期19710-19715,共6页Advances in Clinical Medicine

摘　　要：甲状腺癌(Thyroid Carcinoma, TC)来源于甲状腺上皮细胞,以甲状腺乳头状癌(Papillary Thyroid Carcinoma, PTC)最为常见,是内分泌系统和头颈部肿瘤中最常见的恶性肿瘤,多发于女性。细胞角蛋白19 (Cytokeratin-19, CK-19)定位于细胞质属中间丝蛋白家族,当细胞癌变时CK-19含量升高并被释放出来,使组织液、血液中的浓度升高。白细胞分化抗原56 (Cluster of Differentiation-56, CD-56)是一组相关的细胞表面糖蛋白,在甲状腺乳头状癌中基本上都呈阴性。研究发现,病理学能够鉴别诊断大部分PTC,但是在少数情况下,病理诊断并不明朗,往往需要借助免疫组化染色的手段来辅助病理诊断。CK-19、CD-56的联合应用有助于提高PTC的诊断。Thyroid carcinoma (TC) originates from thyroid epithelial cells, with papillary thyroid carcinoma (PTC) being the most common malignant tumor in the endocrine system and head and neck tumors, often occurring in women. Cytokeratin-19 (CK-19) is located in the intermediate filament protein family of the cytoplasm. When cells undergo cancerous transformation, the content of CK-19 in-creases and is released, causing an increase in concentration in tissue fluid and blood. Cluster of Differentiation Antigen-56 (CD-56) is a group of related cell surface glycoproteins that are generally negative in papillary thyroid cancer. Research has found that pathology can differentiate and diag-nose most PTCs, but in a few cases, the pathological diagnosis is not clear and often requires the use of immunohistochemical staining to assist in pathological diagnosis. The combined application of CK-19 and CD-56 can help improve the diagnosis of PTC.

关 键 词：甲状腺乳头状癌 细胞角蛋白19 白细胞分化抗原56 免疫组化 

分 类 号：R73[医药卫生—肿瘤]